Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

May 1, 2024

https://www.prnewswire.com/news-releases/lipocine-announces-completion-of-dosing-in-pivotal-study-of-postpartum-depression-candidate-lpcn-1154-302132497.html

Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024

Topline results anticipated late in 2Q 2024

SALT LAKE CITY, May 1, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that dosing of subjects has been completed in the pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154. LPCN 1154, oral brexanolone, is being developed as a treatment of postpartum depression (PPD).  Lipocine anticipates topline results late in the second quarter of 2024, with the goal of NDA submission by the end of the fourth quarter of 2024.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.